Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Liraglutide and Mazdutide — mechanism, side effects, legal status, and pricing.
Liraglutide is an FDA-approved GLP-1 receptor agonist marketed as Victoza (type 2 diabetes, approved 2010) and Saxenda (chronic weight management, approved 2014). It was the first GLP-1 analog approved for obesity and carries an FDA boxed warning for the risk of thyroid C-cell tumors. Pediatric indications include type 2 diabetes in patients ≥10 years (Victoza) and obesity in patients ≥12 years with BMI ≥95th percentile (Saxenda).
Mazdutide is a dual GLP-1 / glucagon receptor agonist licensed from Eli Lilly to Innovent Biologics for Greater China. Approved by China's NMPA in June 2025 for chronic weight management and in September 2025 for glycemic control in type 2 diabetes; NOT FDA-approved in the US.
Liraglutide
Mazdutide
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Liraglutide
1 vendor lists this, but none clear the trust bar (score ≥70) yet.
Check Liraglutide prices →Mazdutide
COA corpus from Disclosed Labs — independently tested batches only.
Liraglutide
No COA data yet.
Submit testing data →Mazdutide
6
COAs
99.7%
Avg purity
4
Labs
The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., NEJM 2015; PMID 26132939) demonstrated ~8% body-weight loss at 3.0 mg daily over 56 weeks, and the SCALE Diabetes trial (Davies et al., JAMA 2015; PMID 26284720) showed 6.0% weight loss in adults with type 2 diabetes. The LEADER cardiovascular outcomes trial (Marso et al., NEJM 2016; PMID 27295427) demonstrated a 13% relative reduction in major adverse cardiovascular events in type 2 diabetes with established CVD or high CV risk. A pediatric Phase 3 trial (Kelly et al., NEJM 2020; PMID 32233338) supported Saxenda's FDA approval for adolescents ≥12 years with obesity. While less effective than newer GLP-1 agonists for weight loss, liraglutide has the longest track record and most extensive real-world safety data. The daily dosing requirement is its main disadvantage versus weekly semaglutide.
Key references
Phase 3 GLORY-1 (Ji et al., NEJM 2025) in 610 Chinese adults with obesity/overweight reported mean weight loss of ~11.0% (4 mg) and ~14.0% (6 mg) vs +0.3% placebo at 48 weeks. Additional Phase 3 programs (GLORY-2 obesity, DREAMS-1/2/3 T2DM) supported the NMPA approvals; a 9 mg supplementary application for moderate-to-severe obesity is under NMPA review.
Liraglutide and Mazdutide are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs